cancer risk. The GSTM1 gene is one of the most extensively The A-G polymorphism at codon 104 in the glutathione Sstudied concerning metabolic polymorphisms and cancer risk.
transferase P1 (GSTP1) gene was examined in 138 male
About 50% of the Caucasian population is homozygous for a lung cancer patients and 297 healthy controls. The patients deletion in the gene which makes the enzyme inactive (null had significantly higher frequency of the GG genotype genotype) (4, 5) . The gene product is suggested to be particu-(15.9%) and a lower frequency of AA (38.4%) than the larly important for detoxifying epoxides of certain carcinogenic controls (9.1% and 51.5%, respectively). The level of PAH compounds (1, 6) . Several case-control studies have hydrophobic DNA-adducts were determined in lung tissue indicated that the GSTM1 null genotype is associated with from 70 current smokers. Patients with the GG genotype increased lung cancer risk (7) . However, conflicting results are had a significantly higher adduct level than patients with also published, which at least may be interpreted as indicating AA (15.5 ⍨ 10.2 vs 7.9 ⍨ 5.1 per 10 8 nucleotides, P ⍧ that the effect of this single genetic polymorphism on cancer 0.006). We also analyzed the deletion polymorphism in the risk is low. Other studies have indicated that presence of intact GSTM1 gene in 135 male patients and 342 controls. The GSTM1 gene may be protective for cytogenetic damage (8) patients were stratified according to histology, smoking and carcinogen-derived DNA adduct formation (6, 9, 10) . Our dose, age, adduct level and mutational types found in the recent study on DNA-adduct levels in normal lung tissue from tumors (Ki-ras and p53 genes). The results consistently lung cancer support this conclusion (11) . Since GSTM1 is only indicated that the GSTM1 null genotype was associated weakly expressed in lung tissue (1, 3) , the mechanisms of its with a slightly increased lung cancer risk. When the protective role in this tissue is still insufficiently understood. combined GST M1 and P1 genotypes were examined,
The major GST protein in human lung is GSTP1-1 (1,3). patients with the combination null and AG or GG had
The enzyme is active towards many epoxides of PAHs (1, 6) . significantly higher adduct levels than all other genotype Thus it may in theory compensate for loss of GSTM1 activity.
combinations (P ⍧ 0.011). The distribution of combined
Increased expression of the GSTP1 gene has been found in genotypes was also significantly different in cases and tumors in several tissues including lung (1) . The gene is also controls, mainly due to increased frequency of the combinasuggested to be involved in the development of acquired tion GSTM1 null and GSTP1 AG or GG among patients.
resistance towards anti-cancer drugs (1, 12) . A polymorphic site at codon 104 (A to G substitutions replacing isoleucine with valine) in the P1 gene is known which change the kinetic Introduction properties of the enzyme (13) . In a recent case-control study the GG genotype was significantly more frequent among Tobacco smoke contains several thousand chemicals of which patients with bladder and testicular cancer, and the AA about 50 compounds are known carcinogens. The most importgenotype was decreased in prostate cancer (14) . ant carcinogens belong to the groups polycyclic aromatic
In this study of male cancer patients with NSCLC we have hydrocarbons (PAHs*), aromatic amines and nitroso comexamined genotypes of GST M1 and P1 genotypes and their pounds. Rather than the parent compound itself, it is usually relation both to lung cancer risk and DNA adduct levels found metabolites of the carcinogens that initiate cancer. Many of in normal lung tissue. these compounds are oxidized by phase I enzymes, represented by cytochrome P450 enzymes, into reactive metabolites which are detoxified by phase II enzymes. One important class of Materials and methods the latter group is glutathione S-transferases (GSTs). These found no particular patient groups with exceptional genotype
The GSTM1 genotype was determined in genomic DNA, using a PCR method as described previously (16) . The A-G polymorphism at codon 104 distributions when patients with G alleles were grouped.
in the GSTP1 gene was determined by PCR and digestion of the product with
The hydrophobic DNA adduct levels were determined in Alw261 as described by Harries et al. (14) . One hundred and thirty-three normal lung tissue from 70 current smoking lung cancer patients and 297 controls were analyzed for both genotypes. DNA adducts patients as described in Materials and methods. When the were measured in normal lung tissues from 70 patients by 32 P-postlabelling patients were grouped according to their GSTP1 genotype, analysis with the nuclease P 1 modification (17) . All these patients were current smokers. Data from 38 of these cases have been published previously (16) . significantly higher mean adduct levels were found in patients
The two-dimensional thin layer chromatography of 32 P-postlabelled DNA with one or two G alleles compared to those with the AA digests displayed diagonal zones characteristic of DNA adducts formed from genotype (Table II ). The highest DNA adduct level was found complex mixtures of aromatic and/or hydrophobic compounds. Tumor DNA in the GG group, however, not statistically different from the from 112 male patients was screened for mutations in exon 1 of the Ki-ras gene using PCR and a minigel SSCP method (18) . Samples with aberrantly AG group (P ϭ 0.39). Analysis of variance in log transformed migrating bands were sequenced using Sequenase 2.0 and conditions described data indicated a linear trend in the adduct level with increasing by the supplier (USB, Cleveland, OH). Previously published mutational data number of G alleles (Table II) . The patients were also ranked from exons 4-9 in the p53 gene were used from 83 male patients (19). according to the lung adduct levels. The relationship between Chi-squared test and Fisher's exact test were used in frequency analysis. Two-sided P-values are given when not indicated otherwise. The comparison adduct level and GSTP1 genotype was also confirmed when of means were performed by t-test and ANOVA.
the genotype distribution was analyzed in the upper and lower tertile adduct group (Table II) . Patients with the lowest level Results of hydrophobic DNA adducts (lower tertile group), contrary to those with high levels, had a genotype distribution very We have examined the A-G polymorphism at codon 104 in similar to the healthy controls. The AA genotype of GSTP1 the GSTP1 gene in 138 male cancer patients with primary could therefore partially protect the DNA from being damaged NSCLC. When the genotype distribution was compared with by reactive hydrophobic (PAH) compounds. data from 297 healthy male controls (Table I) , a statistically
We found an increased incidence of the GSTM1 null genosignificant difference was found (χ 2 ϭ 7.49, P ϭ 0.024, 2df).
type among lung cancer patients; however, this was not This difference was due mainly to the homozygous genotypes statistically different from that found in 342 healthy controls AA and GG which contributed to~90% of the total χ 2 value.
( Figure 1 ). Matching the control group with respect to age and As indicated in Table I lung cancer patients had significantly smoking dose (see Materials and methods) did not change this lower incidence of the AA genotype and higher incidence of conclusion. The patients were also stratified by histology, age GG compared to controls. When the controls were matched and smoking dose. The null genotype was most prevalent in with respect to age and lifetime smoking dose (see Materials squamous cell carcinomas and in patients smoking Ͻ20 and methods), similar results were obtained (113 control packyears (lowest quartile group) and among those below 56 subjects). This indicated that individuals with the GSTP1 GG years of age (lowest quartile group) (Figure 1 ). When data on genotype may be more susceptible than those with AA. An hydrophobic DNA adduct levels were analyzed in relation to odds ratio of 1.90 was obtained when the GG genotype was the GSTM1 genotypes, a higher mean level was found in compared with AG and AA in cases and controls (Table I) .
patients with the null genotype than among those with at least When the patients were stratified according to the two major one intact GSTM1 allele (12.5 Ϯ 8.5 and 9.4 Ϯ 6.0 adducts histological tumor types, it appeared that the described difference was found in the group of squamous cell carcinomas, per 10 8 nucleotides, respectively, P ϭ 0.088, T ϭ 1.72). This (Table I) : 2 sided P ϭ 0.002; odds ratio, 5.05; 95% confidence interval, 1.68Ϫ12.20.
Fig. 1.
Frequency of GSTM1 null genotype in male lung cancer patients analyzed in indicated subgroups. Hydrophobic DNA adducts were measured in normal lung tissue from 70 current smokers. The adduct levels were ranked according to size and the GSTM1 null genotype frequency determined in the upper 33 percentile (with highest adduct level) and in the lower 33 percentile. Mutations in the p53 (exons 4-9) and Ki-ras (exon 1-2) genes were analyzed in tumors from 83 and 112 male lung cancer patients, respectively. Patients were grouped according to the mutational types (transversions at G:C base pairs and transitions) found in either one or both genes. In cases where different types were found in the two genes, the patient was included in both groups (3 cases). The genotype distribution in groups represented by solid bars were compared to all controls. The results of the statistical analysis are given above the bars.
tendency was also confirmed when the GSTM1 genotype other genotype combinations (9.35 Ϯ 5.98 per 10 8 nucleotides, P ϭ 0.011, t ϭ 2.61, 68 df). distribution in the highest and lowest tertile adduct groups was analyzed (Figure 1 ). The overall pattern in the data consistently When the frequencies of combined genotypes were compared in patients and control, a significant different distribution was indicated that the null genotype may be associated with a slightly increased lung cancer risk. The different genotype found (P ϭ 0.013, Table III ). The chi square test showed the largest deviation from the expected values in the group distribution found in patients with transversion and transition mutations in the p53 and Ki-ras genes (Figure 1 ) also supports with the combination GSTM1 null and GSTP1 AG or GG, accounting for~60% of the χ 2 value. The data also indicated this conclusion. Transversion mutations at G:C base pairs have been particularly associated with certain carcinogenic PAH that the GSTM1 null genotype was increased relative to controls only among patients with at least one G allele of the compounds (20,21) which are also known to be metabolized by the GSTM1 enzyme (1, 6) . (The two mentioned mutational GSTP1 gene (Table III) . This could indicate an interaction between GSTM1 and P1 genotypes. However, the homogeneity types had similar distribution of GSTP1 genotypes.)
In the last part of this study we examined the effect of the test of odds ratios in cases and controls gave statistically insignificant differences and could therefore not confirm any combined genotypes of GSTP1 and GSTM1. The lowest level of hydrophobic DNA adducts was found among patients with interaction concerning cancer risk. GSTM1 positive and GSTP1 AA genotypes (6.68 Ϯ 3.57 per 10 8 nucleotides). The highest level was found in the group Discussion with the combination GSTM1 null and GSTP1 GG (19.03 Ϯ 11.04 per 10 8 nucleotides). However, since it was Presently, the GSTM1 gene is probably the most well studied gene in relation to metabolic polymorphism and lung cancer only six cases in the latter group, we pooled the adduct data from patients homozygous and heterozygous for the G allele risk, although conflicting results exist. In a recent meta-analysis of 12 case-control studies comprising total 1593 cases and (14.02 Ϯ 9.03 per 10 8 nucleotides). The patients with that genotype combination (GSTM1 null and GSTP1 AG or GG) 2135 controls it was concluded that GSTM1 deficiency was a moderate risk factor for lung cancer development with an odds had significantly higher adduct levels when compared with all a Homogeneity test of odds ratio in the case and control group: P ϭ 0.39, common or ϭ 1.12, 95% CI (0.77 Ϫ 1.65). b Distribution of combined genotypes in cases versus controls: χ 2 ϭ 10.84, df ϭ 3, P ϭ 0.013. c GSTP1 (AG or GG) ϩ GSTM1 null against all other genotype combinations in patients versus controls: 2 sided P ϭ 0.003; odds ratio, 1.96; 95% confidence interval, 1.26 Ϫ 3.06.
ratio of 1.41 (7). A similar risk was estimated in this study associated with the GSTM1 genotypes where distinction between individuals with one and two intact alleles may be (odds ratio 1.33) although statistical significance was not present, probably because larger number of subjects are necesdifficult due to methodological reasons. Both GST M1 and P1 are known to catalyze detoxification sary for detecting such a low increase in cancer risk. It is suggested that the influence of genetic factors may be more of PAHs in vitro, however, they may be differently expressed in different tissues (1, 3) . The expression of GSTM1 is high in pronounced among patients who contract lung cancer at younger age and after relatively lower smoking doses. In this the liver, but the level in lung is very low. The opposite pattern is found for the P1 gene. Increased lung cancer risk associated study the highest frequency of null genotype was found in these groups. In individuals which lack the protective role of with lack of GSTM1-1 activity may therefore be explained by an important role for the liver in the metabolism of compounds GSTM1 (null genotype) a greater fraction of the relevant carcinogens in the cigarette smoke may theoretically reach entered through the lung (6) . According to these suggestions the lung tissue are exposed to carcinogens both from the lumen cellular DNA and form carcinogenic adducts. The examination of genotypes in relation to the level of hydrophobic DNA side and from the bloodstream by metabolites recirculated from the liver. The higher incidence of the susceptible genotypes of adducts in normal lung tissue from patients may support the moderate cancer susceptibility associated with the null both GST M1 and P1 in patients with squamous cell carcinomas may be in accordance with other studies indicating a more genotype. There is no simple relationship between adduct levels and cancer risk. However, animal studies have indicated crucial role for the GST metabolism in the more proximal parts of the lung where squamous cell carcinomas are usually that high levels of stable DNA adducts in the target tissue are associated with increased probability that tumors will occur located (3, 6, 23) . Since several GSTM genes are localized in a cluster on chromosome 1p (24) , it is also possible that the (22). The examination of GSTM1 genotypes in several stratified patients group usually gave only weak statistical significance actual gene studied is not only M1 but also the effect of other genes of this family expressed in the lung tissue (23, 25) . for each group, however, the overall pattern in the data consistently indicated that the null genotype may be associated
Immunohistochemical data have revealed large interindividual variations in the expression of M3 gene in lung (3) . There is with a slightly increased risk. In the above analysis patients were compared to controls matched with respect to ethnic also an indication that the activity or lack of activity of the GSTM1-1 may affect the expression (inducibility) of CYP1A1, background and gender but not by age and smoking dose. The average age and smoking dose of the controls was lower than probably through regulatory mechanisms (26). This CYP gene is essential for the metabolism of many carcinogenic PAH for the patients. About one third of the controls were also nonsmokers. Since lung cancer is strongly related to long-lasting compounds. Lung cancer patients who were recent smokers had significantly induced aryl hydrocarbon hydroxylase (AHH) smoking, some of the controls could therefore be in the patient group if they had been older and smoked more and longer.
activities in lung parenchyma compared with smoking noncancer patients (27,28). Concerning DNA adduct formation, Since the present analysis indicated higher frequency of null genotype among patients than in unmatched controls, this the level of adducts in recent smokers seemed to be positively correlated to AHH (CYP1A1) activity in lung tissue (27,28). probably means that matching the controls would have given even larger differences. The genotype distribution in a control
Irrespective of mechanisms and genes involved, our data may indicate that the null genotype of GSTM1 has less group which matched with the average age and smoking dose of patients was very similar with the whole control group.
penetrance as a risk factor for lung cancer than genotypes of GSTP1. However, also for the GSTP1 it remains to clarify the This is not in conflict with the low effect of the null genotype concerning lung cancer risk.
role of the A to G substitution at codon 104. This results in an isoleucine to valine substitution in the hydrophobic binding When we examined the codon 104 polymorphism of the GSTP1 gene in the same material, it appeared that patients region in the protein, which seems to give only a moderate change in its catalytic properties (13) . This polymorphism may had significantly lower frequency of the AA and higher frequency of the GG genotype than controls. Thus individuals therefore be linked to other features in the P1 gene. In contrast to GSTA1/A2 and GSTM3, the expression level of P1 in the homozygous for the G allele may be of increased cancer risk. This is also supported by the data from measurement of DNA lung seems to be rather constant between individuals (23, 29) . There is some theoretical support that biotransformation of adduct levels in lung tissue. Due to the low frequency of the GG genotype in the population, an extended study is necessary certain mutagens may be affected both by GSTM1 and GSTP1 enzymes. The significance of combined genotypes at these to get a reliable estimate of lung cancer risk for homozygous and heterozygous. A similar problem is present for the risk two genloci concerning DNA damage and cancer risk remains to be clarified. Our data indicate that this is a relevant and 
